Astute granted bioMerieux semi-exclusive, worldwide rights to develop and commercialize Astute’s NephroCheck test for early risk assessment of acute kidney injury on bioMerieux’s Vidas diagnostic platform. NephroCheck is an immunoassay for insulin-like growth factor (IGF)...

Vida Diagnostics Inc. , Iowa City, Iowa Business: Diagnostic Hired: Philippe Raffy as chief technology officer WIR Staff Diagnostic...